How big is the Biologics CDMO Market?

The Biologics CDMO Market size is expected to reach USD 18.17 billion in 2024 and grow at a CAGR of 10.87% to reach USD 30.45 billion by 2029. Read More

What is the current Biologics CDMO Market size?

In 2024, the Biologics CDMO Market size is expected to reach USD 18.17 billion. Read More

Which is the fastest growing region in Biologics CDMO Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Biologics CDMO Market?

In 2024, the North America accounts for the largest market share in Biologics CDMO Market. Read More

What years does this Biologics CDMO Market cover, and what was the market size in 2023?

In 2023, the Biologics CDMO Market size was estimated at USD 16.19 billion. The report covers the Biologics CDMO Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Biologics CDMO Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

What future trends are expected in the Biologics CDMO market?

Major trends in the Biologics CDMO Market are a) Increased adoption of single-use technologies b) Focus on personalized medicine c) Expansion in emerging markets Read More

Biologics CDMO Market Share

Statistics for the 2023 & 2024 Biologics CDMO market share, created by Mordor Intelligence™ Industry Reports. Biologics CDMO share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Biologics CDMO Industry

The biologics contract development and manufacturing organization (CDMO) market is highly fragmented due to the presence of both global players and small and medium-sized enterprises. Some of the major players in the market are Boehringer Ingelheim Group, Wuxi Biologics (Cayman) Inc., Samsung Biologics, Lonza Group Ltd, and Fujifilm Diosynth Biotechnologies USA Inc. Players in the market are adopting strategies such as partnerships and acquisitions to enhance their product offerings and gain sustainable competitive advantage.

In March 2024, WuXi Biologics, a global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that it had broken ground on its 13.5-hectare CRDMO center in Tuas Biomedical Park in Singapore. The center will provide integrated biologics research and development along with manufacturing services. The CRDMO site also includes an additional 120,000L manufacturing capacity to WuXi Biologics’ global network.

In January 2024, Boehringer Ingelheim, the research-driven biopharmaceutical company, announced an expansion and upgrade of its plant in Koropi, Greece. The company announced an increase in the manufacturing capacity of new and existing medications that are in late-stage development, with an investment of EUR 120 million (USD 129.99 million).